DIFFUSION PHARMACEUTICALS IN (DFFN)
US2537484048 - Common Stock
| MRQ (2023-6-30) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | 1.32M | N/A | N/A | N/A | N/A | |||
| Cash Equivalents | 13.68M | 10.11M | 37.31M | 18.52M | 14.18M | |||
| Marketable Securities | 0.00 | 12.41M | N/A | N/A | N/A | |||
| Other Current Assets | 695.07K | 112.41K | 510.02K | 260.83K | 470.00K | |||
| Total Current Assets | 15.69M | 22.64M | 37.82M | 18.78M | 14.65M | |||
| Non-Current Assets | ||||||||
| PPE Net | N/A | N/A | 0.00 | 298.36K | 500.00K | |||
| Goodwill | N/A | N/A | N/A | N/A | N/A | |||
| Intangibles | N/A | N/A | 0.00 | 8.64M | 8.64M | |||
| Other Non-Current Assets | N/A | 0.00 | 15.58K | 15.77K | 320.00K | |||
| Total Non-Current Assets | 0.00 | 0.00 | 15.58K | 8.95M | 9.46M | |||
| TOTAL ASSETS | 15.69M | 22.64M | 37.84M | 27.73M | 24.11M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | N/A | N/A | N/A | N/A | |||
| Accrued Expenses | 532.55K | 1.29M | 1.98M | 1.89M | 470.00K | |||
| Accounts Payable | 932.43K | 1.13M | 947.50K | 545.84K | 1.25M | |||
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | |||
| Total Current Liabilities | 1.46M | 2.42M | 2.93M | 2.44M | 1.72M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Deferred Taxes/Income | N/A | N/A | 0.00 | 443.89K | 2.12M | |||
| Other Non-Current Liabilities | N/A | N/A | 0.00 | 35.69K | 140.00K | |||
| Total Non-Current Liabilities | 0.00 | 0.00 | 0.00 | 479.59K | 2.26M | |||
| TOTAL LIABILITIES | 1.46M | 2.42M | 2.93M | 2.92M | 3.98M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -151.80M | -145.60M | -130.01M | -105.91M | -91.72M | |||
| Additional Paid In Capital | 166.03M | 165.85M | 164.81M | 130.66M | 111.82M | |||
| Minority Interest | N/A | N/A | N/A | N/A | N/A | |||
| Common Shares | 2.04K | 2.04K | 101.91K | 64.02K | 30.00K | |||
| Other Shareholders' Equity | 0.00 | -35.38K | N/A | N/A | N/A | |||
| Shares Outstanding | 2.04M | 2.04M | 2.04M | 1.28M | 33.48M | |||
| Tangible Book Value per Share | 6.97 | 9.91 | 17.13 | 12.63 | 0.34 | |||
| Total Shareholders' Equity | 14.23M | 20.22M | 34.91M | 24.81M | 20.13M | |||
| TOTAL LIABILITIES AND EQUITY | 15.69M | 22.64M | 37.84M | 27.73M | 24.11M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | N/A | |||
| Current Ratio | 10.71 | 9.36 | 12.92 | 7.71 | 8.52 | |||
| Return On Assets (ROA) | -83.34% | -68.88% | -63.68% | -58.19% | -48.94% | |||
| Return On Equity (ROE) | -91.92% | -77.12% | -69.02% | -65.03% | -58.62% | |||
All data in USD